The estimated Net Worth of Todd C Cozzens is at least $2.45 Million dollars as of 25 May 2022. Mr. Cozzens owns over 2,614 units of Natera Inc stock worth over $1,958,124 and over the last 8 years he sold NTRA stock worth over $0. In addition, he makes $494,356 as Independent Director at Natera Inc.
Todd has made over 5 trades of the Natera Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 2,614 units of NTRA stock worth $323,692 on 25 May 2022.
The largest trade he's ever made was exercising 49,475 units of Natera Inc stock on 9 March 2021 worth over $68,770. On average, Todd trades about 7,031 units every 69 days since 2016. As of 25 May 2022 he still owns at least 15,813 units of Natera Inc stock.
You can see the complete history of Mr. Cozzens stock trades at the bottom of the page.
Todd C. Cozzens serves as Independent Director of the Company. Mr. Cozzens is the co-founder and managing partner of Transformation Capital Partners, L.P., a a growth equity fund focused on healthcare information technology and services companies. Transformation Capital Partners, L.P. is the successor management company to Leerink Transformation Partners, which Mr. Cozzens also co-founded and of which he served as managing partner since its inception in 2016. Prior to forming Leerink Transformation Partners, Mr. Cozzens co-led healthcare investing at Sequoia Capital, a venture capital firm, from 2012 to 2015, and prior to that led several business areas with Optum, a subsidiary of UnitedHealth Group, including strategy and M&A. From 2000 to 2010, Mr. Cozzens was the co-founder and served as chief executive officer of Picis Inc., a provider of electronic medical record software to hospitals, until it was acquired by the UnitedHealth Group in 2010 and subsequently became a division of Optum. Mr. Cozzens currently serves on the boards of directors of a number of private companies. Mr. Cozzens holds a Bachelor of Arts degree from Marquette University, and completed the Program for Management Development at Harvard University. Our board of directors believes that Mr. Cozzens is qualified to serve as a director based on his financial and managerial experience, his service on private company boards of directors and his experience with healthcare technology and information systems. Mr. Cozzens currently serves as the chair of our compensation committee and also serves on our audit committee.
As the Independent Director of Natera Inc, the total compensation of Todd Cozzens at Natera Inc is $494,356. There are 13 executives at Natera Inc getting paid more, with Steven Chapman having the highest compensation of $6,200,910.
Todd's mailing address filed with the SEC is C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN, TX, 78753.
Over the last 14 years, insiders at Natera Inc have traded over $290,138,276 worth of Natera Inc stock and bought 2,046,493 units worth $38,018,986 . The most active insiders traders include Matthew Rabinowitz, James Healy, and Roelof Botha. On average, Natera Inc executives and independent directors trade stock every 9 days with the average trade being worth of $3,415,231. The most recent stock trade was executed by Steven Leonard Chapman on 15 August 2024, trading 5,583 units of NTRA stock currently worth $663,875.
natera is a san carlos, ca-based company that is driven by a passion for elevating the science and utility of prenatal testing. the advent of the information age has created a paradigm shift in the fields of computing and informatics. surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. until natera. from conception to delivery, natera is pioneering next-generation accuracy and reliability in preconception and prenatal genetic testing services, enabling couples to be informed about their pregnancy each step of the way. the company offers a wide range of tests from preimplantation genetic diagnosis (pgd) for ivf to breakthrough advances in the field of non-invasive prenatal testing (nipt). using advances from the human genome project and powered by sophisticated proprietary bioinformatic algorithms, natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the
Natera Inc executives and other stock owners filed with the SEC include: